Journal article
Single nucleotide polymorphisms in the toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine
CE Moore, BJ Hennig, KP Perrett, JC Hoe, SJ Lee, H Fletcher, D Brocklebank, D O'Connor, MD Snape, AJ Hall, S Segal, AVS Hill, AJ Pollarda
Clinical and Vaccine Immunology | AMER SOC MICROBIOLOGY | Published : 2012
DOI: 10.1128/CVI.05379-11
Abstract
The rate of decay of antibody concentration following serogroup C meningococcal (MenC) polysaccharide-protein conjugate vaccination varies between individuals. This depends partly on vaccination age but may be influenced by human genetics. We studied 721 single nucleotide polymorphisms (SNPs) across 131 candidate genes in a first cohort of 905 Caucasians (11 to 21 years old; mean time after vaccination, 4.9 years) and 30 SNPs across 17 genes in a replication study using 155 children, aged 6 to 12 years (mean time after vaccination, 6.7 years), and 196 infants (1 year old; mean time after vaccination, 8 months). Individuals were classified as responders or nonresponders for total MenC IgG con..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
[ "This work was supported by Novartis Vaccines and Diagnostics (NVD), who funded the initial clinical study and genotyping. NVD also provided funding and sponsorship for the infant study, allowing DNA collection by the investigators. GlaxoSmithKline Biologicals and the Oxford Partnership Comprehensive Biomedical Research Centre provided funding for the clinical study of 6- to 12-year-old children, which was sponsored by Oxford University, facilitating DNA collection. M.D.S. was funded by the Oxford Partnership Comprehensive Biomedical Research Centre, with funding from the NIHR Biomedical Research Centre Programme, which, with the NIHR Thames Valley Comprehensive Local Research Network, also provides support to the Oxford Vaccine Group.", "M.D.S. has received financial assistance from Novartis Vaccines and GlaxoSmithKline to attend conferences and has had travel and accommodation expenses paid by Novartis Vaccines while working in collaboration with Novartis Vaccines in Siena, Italy. A.J.P. acts as chief and principal investigator for clinical trials conducted on behalf of Oxford University, sponsored by vaccine manufacturers, including Novartis Vaccines and GlaxoSmithKline, but does not receive any personal payment from them. Industry-sourced honoraria for lecturing or writing and travel expenses and grants for educational activities are paid directly to an independent charity or an educational/administrative fund held by the Department of Paediatrics, University of Oxford." ]